The decline in CD4+ T cell proportion following CRT may suggest impaired cell-mediated immunity, while the rise in CD8+ T cell proportion could be linked to the activation triggered by the release of tumor-associated antigens prompted by CRT. The gene discussed is CD8A; the disease is neoplasm.